Description of the medicine: Gonadotropin menopausal (Gonadotropinum menopausticum)
Gonadotropin Menopause (Gonadotropinum menopausticum).
Synonym: Gonadotropinum menopausalis.
Powder gray with a brownish tint. Soluble in water. Activity is determined biologically (by the ability to stimulate ovarian growth in immature female rats against the background of the introduction of chorionic gonadotropin); 1 mg of the drug contains at least 10 units.
Menopause ganadotropin for injection (Gonadotropinum menopausticum pro injectionibus) is a lyophilized sterile powder that is ex mempore dissolved in a sterile isotonic (0.9%) sodium chloride solution. One bottle contains 75 units.
The drug is used for infertility in women with ovarian hypofunction and anovulatory cycles (primary or secondary amenorrhea of central origin, hypomenstrual syndrome). With Skien's syndrome, as well as in men with infertility of endocrine genesis (hypogonadotropic hypogonadism, eunuchoidism).
Menopause gonadotropin is administered intramuscularly.
In the treatment of infertility in women, 75 or 150 IU are administered per day (in 1 or 2 ml of isotonic sodium chloride solution) for 10 days or longer until the signs of complete maturation of the follicle appear. In order to determine the optimal dose of the drug, it is recommended that the level of estrogen in the blood and urine be determined daily during the treatment process. If this is not possible, the functional state of the ovaries is judged by tests of functional diagnostics (a pronounced symptom of the pupil, etc.). 24-48 hours after the end of injection of the drug, patients are prescribed chorionic gonadotropin at 1500 - 3000 IU per day intramuscularly for 3 days.
In male infertility, menopausal gonadotropin is prescribed at 75 units in combination with chorionic gonadotropin at 1000 to 2000 units.
Both drugs are administered intramuscularly every other day for 90-120 days.
Treatment should be carried out under close medical supervision. With excessive stimulation of the ovaries, an increase in their size and the appearance of pain in the pelvic region, an increase in the excretion of estrogen in the urine are possible. When signs of ovarian hyperstimulation appear, drug administration is stopped.
Release form: on 75 PIECES in bottles with a capacity of 5 ml, corked with rubber stoppers and rolled in aluminum caps in a package of 5 bottles and 5 ampoules (1 ml) of isotonic sodium chloride solution.
Storage: List B. In a dry, dark place at a temperature of no higher than + 20 C.